Position in JNJ
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$12,902,437
+$2,098,189 QoQ
Shares Held
50,803
+14.9% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
2.97%
of 13F equity value
Holder Rank
#959
of 4,676 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026TrueMark Investments, LLC holds $39,739,215 across 7 Drug Manufacturers - General names. JNJ ranks #1 (32.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
This page
|
50,803 | $12,902,437 | |
| 2 | ABBV |
AbbVie Inc.
|
37,043 | $9,321,500 | |
| 3 | GSK |
GSK plc
|
108,899 | $5,708,485 | |
| 4 | SNY |
Sanofi
|
125,869 | $5,369,571 | |
| 5 | AZN |
Astrazeneca PLC
|
18,998 | $3,602,400 | |
| 6 | NVS |
Novartis AG
|
12,800 | $2,006,016 | |
| 7 | LLY |
ELI LILLY & Co
|
691 | $828,806 |
All Filings in JNJ
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,902,437 | 50,803 | Shares | Sole | 2026-07-22 | |
| 2026-03-31 | $10,804,248 | 44,200 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $8,603,532 | 41,573 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $7,155,543 | 38,591 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $4,772,215 | 31,242 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $6,391,805 | 38,542 | Shares | Sole | 2025-04-22 | |
| 2024-12-31 | $5,033,788 | 34,807 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $3,793,500 | 23,408 | Shares | Sole | 2024-10-16 | |
| 2024-06-30 | $2,595,363 | 17,757 | Shares | Sole | 2024-07-29 | |
| 2024-03-31 | $1,445,698 | 9,139 | Shares | Sole | 2024-04-15 | |
| 2023-12-31 | $1,458,152 | 9,303 | Shares | Sole | 2024-01-11 | |
| No filing history on record for this holder in this stock. | ||||||